Sphera Funds Management Ltd. Aeglea Bio Therapeutics, Inc. Transaction History

Sphera Funds Management Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.29 - $0.61 $59,635 - $125,441	205,641 Added 46.65%	646,478 $187,000
Q4 2022 Feb 14, 2023	BUY	$0.35 - $1.54 $154,292 - $678,888	440,837 New	440,837 $198,000
Q3 2019 Nov 14, 2019	SELL	$6.42 - $9.0 $1.2 Million - $1.68 Million	-187,206 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$6.1 - $8.78 $4.81 Million - $6.92 Million	-787,794 Reduced 80.8%	187,206 $0
Q1 2019 May 15, 2019	BUY	$7.6 - $9.4 $2.85 Million - $3.53 Million	375,000 Added 62.5%	975,000 $7.85 Million
Q4 2018 Feb 14, 2019	SELL	$6.51 - $10.19 $345,759 - $541,211	-53,112 Reduced 8.13%	600,000 $4.49 Million
Q3 2018 Nov 14, 2018	BUY	$8.24 - $11.0 $1.19 Million - $1.58 Million	143,994 Added 28.28%	653,112 $6.25 Million
Q2 2018 Aug 13, 2018	BUY	$7.87 - $10.89 $4.01 Million - $5.54 Million	509,118 New	509,118 $5.39 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.